Ocata Therapeutics, Inc., today announced that it has been granted Advanced Therapy Medicinal Product designation for its RPE therapy for macular degeneration. This designation is an essential step in allowing companies to commercialize products effectively across the European Union.
http://ift.tt/1AIlhlP
http://ift.tt/1AIlhlP
No comments:
Post a Comment